NIH extends PPD HIV research support contract until 2024

By Melissa Fassbender

- Last updated on GMT

NIH extends PPD HIV research support contract until 2024

Related tags Clinical trial Health care Epidemiology

The renewed contract covers a range of research related services, including monitoring therapeutic trials, prevention trials, and vaccines work, with the ultimate goal of an "AIDS-free generation."

Pharmaceutical Product Development, LLC (PPD) has secured a  renewal of its contract with the Division of AIDS (DAIDS​), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the fifth time.

The contracts range from five to seven years and involve monitoring for approximately 150 clinical studies per contract.

The original NIAID/DAIDS contract was awarded 27 years ago, and the latest renewal will extend the clinical trial services relationship until 2024.

Patti McNamara, vice president, government and public health services for PPD, told us the relationship has expanded since 1990.

While the core services have remained the same, the underlying protocols have grown in number, size and complexity as the science has matured​,” explained McNamara.

As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors.

Additionally, she said the contract value has more than tripled for the current contract period versus the contract initially awarded in 1990. The CRO is also now monitoring projects at sites throughout the world.

The extension covers site monitoring for HIV treatment and prevention clinical trials. Sites are located around the world with the highest number in the US and Africa​,” said McNamara.

Over the years, we have partnered with DAIDS to support this important organization’s global research efforts to advance the biological knowledge of HIV/AIDS and its related co-infections and co-morbidities, with the ultimate goal of creating an AIDS-free generation​.”

(Feature image: iStock/Jovanmandic)

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more